Aytu Biopharma (AYTU) Current Assets (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Current Assets data on file, last reported at $67.3 million in Q1 2026.

• On a quarterly basis, Current Assets fell 7.15% year-over-year to $67.3 million in Q1 2026; TTM through Mar 2026 was $67.3 million, a 7.15% decrease from a year earlier, with the FY2025 full-year figure at $79.2 million, up 27.93% from the prior year.
• Current Assets for Q1 2026 stood at $67.3 million, down from $76.2 million in the prior quarter.
• Over the last five years, Current Assets for AYTU reached as high as $81.1 million in Q3 2025 and fell as low as $59.9 million in Q2 2022.
• Historically, Current Assets has averaged $71.1 million across 5 years, with a median of $71.4 million in 2023.
• Across the five-year window, Current Assets slumped 43.05% in 2022 and soared 33.54% in 2025, its largest moves.
• Year by year, Current Assets stood at $70.6 million in 2022, then climbed by 1.08% to $71.4 million in 2023, then decreased by 11.65% to $63.1 million in 2024, then advanced by 20.92% to $76.2 million in 2025, then declined by 11.69% to $67.3 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $67.3 million in Q1 2026, $76.2 million in Q4 2025, and $81.1 million in Q3 2025.